UNSPSC 51401702: Benzoctamine

This classification denotes an anxiolytic with the molecular formula C18H19N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 734MM7Y191, chemically known as 9,10-ethanoanthracene-9(10h)-methylamine, n-methyl-, 9,10-dihydro but generally known as benzoctamine, which bears US NIH Compound Identifier 28425. Benzoctamine most often comes in base and hydrochloride forms. European Medicines Agency schedules Benzoctamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05757MIG.

UNSPSC 51401702 Benzoctamine is a Commodity code that in recent state and local practice covers procurement of pharmaceutical products, including naloxone, generic multi-source pharmaceuticals, and over-the-counter products supplied through authorized wholesale channels to support community health, emergency response, and state healthcare programs. State and local issuing bodies under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. The scope of work spans direct product procurement with specified National Drug Codes, compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and logistics arrangements including quarterly or as-needed deliveries to designated facilities. Vendors must maintain relationships with authorized pharmaceutical wholesalers, provide detailed product specifications and pricing in multiple formats, carry substantial insurance coverage, and demonstrate E-Verify compliance and drug-free workplace certification.

Recent opportunities show activity concentrated in Florida and Minnesota. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, due July 26, 2026) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities including Oregon, with awards effective July 1, 2026 and evaluation weighted 75 percent on price competitiveness. Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) as preliminary market research on direct-to-manufacturer prescription programs, signaling potential future formal procurement in that state.